Osivax
Osivax is a clinical-stage biopharmaceutical company developing vaccines using its novel, self-assembling nanoparticle platform technology, oligoDOMTM, to develop transformative, first-in-class pan-respiratory virus vaccines. The company's goal is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot.
Funding Round: Series B
Funding Amount: €10M
Date: 04-Mar-2025
Investors: Meiji Seika Pharma Co., Ltd, Existing Investors
Markets: Biotech, Pharmaceuticals, Biotechnology Research
HQ: Lyon, France
Founded: 2017
Website: https://osivax.com/
LinkedIn: https://www.linkedin.com/company/osivax
Twitter: https://twitter.com/OsivaxVaccines
Crunchbase: https://www.crunchbase.com/organization/osivax
Leave a Comment
Comments
No comments yet.